Published in Journal of Clinical Investigation · View the paper (DOI)
Prazosin, a low-cost FDA-approved alpha blocker, shows promise in reducing the risk of death from COVID-19-associated hyperinflammation by targeting cytokine storm syndrome. Early clinical trials are recommended to confirm its safety and effectiveness.
Coverage from 2 institutions